Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the ...
Company to participate in Live Virtual Investor Closing Bell segment today, April 16th?at?4:00 PM ET- Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (N ...
The end of the historic Artemis II mission kicks off a race to establish a permanent human presence on the moon.
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria. Approval in CSU for children two to ...
Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic ...
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...
The collegiate sports landscape has led athletic departments to lean on donors and fundraise more than ever, but UGA ...
Evalauting breakout Illinois guard Keaton Wagler.
The end of the historic Artemis II mission kicks off a race to establish a permanent human presence on the moon.
Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be ...
New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned ...
Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results